AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround
In a bid to rejuvenate growth following years of shrinking revenue and the loss of patent protection for its mainstay drugs, AstraZeneca $AZN is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
